Rankings
▼
Calendar
KROS Q2 2019 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KROS
Keros Therapeutics, Inc.
$424M
Q2 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$0
0.0% margin
Operating Income
-$3M
-106.0% margin
Net Income
-$3M
-114.1% margin
EPS (Diluted)
$-0.37
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$13,000
← FY 2019
All Quarters
Q3 2019 →